Arbutus Biopharma (ABUS) Equity Average (2011 - 2026)

Arbutus Biopharma's Equity Average history runs 16 years deep, the most recent figure standing at $168.4 million for Q1 2026.

• In Q1 2026, Equity Average rose 90.77% year-over-year to $168.4 million; the TTM figure through Mar 2026 stood at $168.4 million (up 90.77% YoY), while the FY2025 annual figure was $87.0 million, down 14.48% from the prior year.
• Equity Average came in at $168.4 million for Q1 2026 at Arbutus Biopharma, up from $77.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $168.4 million in Q1 2026 to a low of $77.0 million in Q4 2025.
• A 5-year average of $122.2 million and a median of $118.5 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average slumped 31.62% in 2025 and soared 90.77% in 2026, its largest moves.
• Arbutus Biopharma's Equity Average stood at $141.2 million in 2022, then declined by 20.19% to $112.7 million in 2023, then retreated by 9.36% to $102.1 million in 2024, then declined by 24.62% to $77.0 million in 2025, then surged by 118.71% to $168.4 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $168.4 million, $77.0 million, and $80.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison